ASTRAZENECA sales increased by 50 % in the third quarter, but earnings increased by 50 % this year and increased by 32 % a year.
COVID-19 vaccines are currently expected to be profitable. This group has sold 2.2 billion vaccines since the year began.
-An-ad
“ASTRAZENECA’s scientific leadership has been providing strong profits and exceptional pipeline delivery in eight positive late reading over the seven pharmaceuticals since June.
“The addition of Alexion promotes our commitment to bringing transformation to patients around the world, and I am proud of my colleagues’ continuous dedication and focus.”
Following the results, group shares decreased by 2.62 % (0913 GMT).
“Astrazenka’s revenue reflects an impressive quarterly for major pharmaceutical companies, but abundant growth drivers stand out to this company,” he said. Skeet says.
“In the third quarter of 2021, many major pupils have given the estimated analysts and raised their third quarter guidance. Astraseneca reported the growth of higher product sales than expected. Despite the fact that the analyst’s estimated value was lost and the guidance was maintained, the 32 % CER, excluding vaccine, maintained the 15 % growth of the core EPS. Astraseneka discovered a loss, which was mainly promoted by the investment necessary to support fast -growing pipelines. “
“The top line beats of Astrazenka are impressive, and the context of impressive data from continuous vaccine rollouts, booster doses, and antiviral drugs between Merc and Pfizer probably indicates the normalization of the market environment. I am.
